Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-hydroxycyclofen
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
4-Hydroxycyclofen (also known as cyclofen-OH or 4-OHC) is a synthetic, photostable analog of 4-hydroxytamoxifen (4-OHT). It acts as a potent estrogen receptor (ER) ligand. It is widely used in optochemogenetics and chemical biology as a ligand to control the activity of proteins fused to a mutated estrogen receptor ligand-binding domain (such as Cre-ERT2 or Cas9-ERT2). When caged with photolabile protecting groups (such as DMNPE or Cy7 derivatives), its activity is masked until light-induced uncaging (photo-uncaging) releases the active 4-hydroxycyclofen, enabling precise spatiotemporal control of gene recombination (via Cre/LoxP) or gene editing in vitro and in vivo.
- Other names
- 4-OHCcyclofen-OH
02
Targets
ER (Estrogen receptor)
Beyond the preview
Go deeper on 4-hydroxycyclofen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-hydroxycyclofen.